TORONTO, May 6, 2015 /PRNewswire/ — Axxess Pharma Inc. (OTC: AXXE) a specialty pharmaceutical and nutritional supplements company, is pleased to announce, research firm Murphy Analytics has re-initiated coverage on AXXE and confirmed a “positive outlook” on the company. The positive outlook is based on Axxess Pharmas projected growth and fundamentals.
To view Murphy Analytics May 2015 research report, please click on the link: http://www.murphyanalytics.com/uploads/AXXE_Update_2015.pdf
Murphy Analytics LLC is owned by Patrick J. Murphy, who has nearly 20 years of capital markets experience, providing institutional investment and transaction analysis across a range of asset classes including microcap equities, commercial real estate debt and equity, municipal derivatives and public finance, venture capital, fixed income, CMBS and mortgage REIT’s. In addition to his work with Murphy Analytics, Mr. Murphy also serves as a consultant to a municipal derivatives advisory firm. Mr. Murphy is an alumnus of the University of Notre Dame (1991), with an undergraduate degree in Economics, and earned a Masters Degree in Finance from St. Louis University in 1997. Mr. Murphy is a CFA Charterholder and a member of the CFA Society of St. Louis.
Mr. Murphy stated, “We are providing a positive outlook on Axxess Pharma, Inc. Muscle Pharma’s (MSLP) growth strategy serves as a guide for AXXE to take share in a market expected to grow up to $160 billion. If AXXE can begin to replicate the MSLP’s growth performance in the near term, investors may push the stock past the 52-week high of $0.35.”
Dr. Daniel Bagi, President of Axxess Pharma stated “We are very pleased that Murphy Analytics has re-initiated coverage with a ‘positive outlook’ on our company.” Dr. Bagi further stated, “We are also very excited that those in the investment community have begun to take notice and will be monitoring our global growth in sales and product line.”
About Axxess Pharma Inc.:
Axxess Pharma Inc. is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess’s goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain, – to optimal health management through improved nutritional supplements.
About Authentic Brands Group, LLC
Authentic Brands Group, is a brand development, licensing, and entertainment company. In conjunction with Leonard Green & Partners, ABG’s mandate to acquire, manage, and elevate long-term value in consumer, celebrity, and media brands. Headquartered in New York City, ABG’s mission is to further enhance brand equity through partnering with best-in-class licensees and retail partnerships. ABG’s global portfolio of world-renowned brands includes Marilyn Monroe®, Mini Marilyn™, Muhammad Ali®, Elvis Presley®, Juicy Couture®, Judith Leiber®, Adrienne Vittadini®, Taryn Rose®, Hickey Freeman®, Hart Schaffner Marx®, Palm Beach®, Misook®, Prince®, Spyder®, Airwalk®, Above The Rim®, Vision Street Wear®, Hind®, Ektelon®, Viking®, Bobby Jones®, Tapout®, Sportcraft®. www.abg-nyc.com.
For more information, please visit www.axxesspharmainc.com, or contact Investor Relations at (973) 351-3868.
Safe Harbor Statement:
Statements about the Company’s future expectations and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words “anticipate,” “estimate,” “expect,” “intend,” “plans,” “projects,” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-firm–murphy-analytics-re-initiates-coverage-on-axxess-pharma-inc-with-positive-outlook-300078431.html
SOURCE Axxess Pharma, Inc
Copyright © 2015 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Source: otc markets